2 Health Care Partnerships Go Head-To-Head

While the partnership between GlaxoSmithKline (NYSE: GSK) and Ligand (NASDAQ: LGND) seems to be moving forward, the partnership between Roche (OTCMKTS: RHHBY) and PDL (NASDAQ: PDLI) has seemingly reached its end

Feb 14, 2014 at 2:30PM

The health care space is full of collaborative arrangements, with many pharmaceutical companies in particular forming partnerships with peers to share the development costs (and risk) involved in developing new drugs and treatments. However, partnerships are not a silver bullet for the challenges that arise when researching new drugs. Let's look briefly at a pair of examples.

A successful partnership
One such partnership that has enjoyed a relatively high degree of success recently is that between GlaxoSmithKline (NYSE: GSK) and Ligand (NASDAQ: LGND), with the two companies collaborating on a drug for which they are seeking additional marketing approval.

Indeed, GlaxoSmithKline's share price has gained 6.5% in February alone and has outpaced the S&P 500 by around 4.5%. A factor behind this has been the news that GlaxoSmithKline's partner, Ligand has received "breakthrough" designation by U.S. regulators for the use of its drug, Promacta, in patients with a rare form of anemia.

The news is encouraging for a drug that Ligand and GlaxoSmithKline already market for other treatments, including chronic hepatitis C and a very rare condition called chronic immune thrombocytopenic purpura, where the body attacks its own platelets. The "breakthrough" status is with regard to another treatment (as mentioned) for a rare form of anemia called severe aplastic anemia, where the bone marrow fails to make enough new blood cells.

The big advantage to receiving 'breakthrough' status is, of course, the extra meetings and earlier communications with the FDA that Ligand and GlaxoSmithKline will now experience. As with GlaxoSmithKline's share price, Ligand has posted gains in February, being up more than 20% since the start of the month as investors look ahead to the outcome of the potential new use for Promacta.

A difficult partnership
Clearly, the partnership between Ligand and GlaxoSmithKline is proving to be beneficial to both companies at the present time. However, the partnership between GlaxoSmithKline's peer Roche (OTCMKTS: RHHBY) and PDL BioPharma (NASDAQ: PDLI) has not been such a smooth ride.

Indeed, just last week the two companies agreed to settle the dispute over royalty rates on a group of drugs that PDL helped to develop. PDL alleged that Roche had underpaid royalties on four cancer drugs: Herceptin, Avastin, Perjeta, and Kadcyla, as well as an eye drug called Lucentis and an asthma treatment called Xolair, a claim that Roche denied.

The two companies have been in disagreement regarding royalties for more than three years but have now agreed that PDL will receive a single royalty rate (as opposed to a declining rate as total sales of the drugs increase, which has been the case in the past) on sales of the drugs until the end of 2015, with the exception of U.S. sales of Lucentis (although PDL will receive royalties on sales of Lucentis outside the U.S. until the end of this year). Furthermore, the dispute over patent protection has also been resolved, with Roche agreeing not to challenge patent protection on the drugs.

Looking ahead
Indeed, partnerships can clearly work well (as in the case of GlaxoSmithKline and Ligand), where two or more companies work together for a common goal. However, with the sheer volume of partnerships in the health care space, there are bound to be instances where events turn sour, as in the case of Roche and PDL.

The positive thing for shareholders in Roche and PDL is that the resolution lifts a cloud from both companies and, although shares did not react particularly positively immediately following the update, the loss of uncertainty is a good thing, meaning 2014 could prove to be a brighter year for both companies.

Meanwhile, for GlaxoSmithKline and Ligand, 2014 looks set to be a very exciting year, with their partnership seemingly highly beneficial for investors in both stocks.

The Motley Fool's top stock for 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information